亚麻醉剂量氯胺酮可有效治疗慢性疼痛急性加重
本研究为随机双盲安慰剂对照试验,2017年5月至2018年6月在公立教学医院纳入慢性疼痛超过3个月且急性加重(VAS≥70 mm)的成人患者,比较0.5 mg/kg氯胺酮、0.25 mg/kg氯胺酮与安慰剂20分钟输注。主要终点为60分钟时VAS下降20 mm,0.5 mg/kg组83%(25/30)、0.25 mg/kg组80%(28/35)达标,安慰剂组41%(13/32),P=0.001。氯胺酮组不良反应更多,0.25 mg/kg组有1例因躁动需约束。24至48小时电话随访未发现组间疼痛评分差异。
要点
- 慢性疼痛急性加重(VAS≥70 mm)成人中,0.5 mg/kg氯胺酮20分钟输注后60分钟83%(25/30)达到VAS下降20 mm的主要终点,安慰剂组41%(13/32),P=0.001。
- 0.25 mg/kg氯胺酮20分钟输注后60分钟80%(28/35)达到主要终点,与0.5 mg/kg组相近,均优于安慰剂。
- 氯胺酮组不良反应多于安慰剂组,0.25 mg/kg组有1例因躁动需使用约束代码。
- 0.5 mg/kg组有3例因不良反应在输注期间退出研究。
- 24至48小时电话随访(89%受试者)未检测到组间疼痛水平差异,氯胺酮未显示更长期的疼痛控制。
适用人群与场景
- 年龄>18岁、慢性疼痛超过3个月且急性加重(VAS≥70 mm)的成人患者,研究在公立教学医院进行。
诊断标准与关键阈值
- 纳入标准:年龄>18岁,慢性疼痛>3个月,急性加重(VAS≥70 mm)。
- 主要终点:100 mm视觉模拟量表(VAS)在60分钟时下降20 mm。
处置流程与药物剂量
- 0.5 mg/kg氯胺酮或0.25 mg/kg氯胺酮或安慰剂,20分钟内输注。
- 在基线及开始研究药物后20、40、60分钟用VAS评估疼痛、躁动和镇静。
- 24至48小时电话随访,使用10点数字评定量表评估疼痛。
研究设计与关键结果
- 随机双盲安慰剂对照试验,2017年5月至2018年6月在公立教学医院进行,共招募106例受试者,排除3例基线疼痛<70 mm者。
- 随机分组:35例接受0.5 mg/kg氯胺酮,36例接受0.25 mg/kg氯胺酮,35例接受安慰剂;0.5 mg/kg组3例因不良反应在输注期间退出,每组1例数据不完整,最终97例纳入分析。
- 基线疼痛评分91.9±8.9 mm,年龄46.5±12.6岁,性别分布和疼痛类型组间相似。
- 主要终点:0.5 mg/kg组25/30(83%)改善,0.25 mg/kg组28/35(80%)改善,安慰剂组13/32(41%)改善,P=0.001。
- 氯胺酮组不良反应更多,0.25 mg/kg组有1例因躁动需约束代码。
- 24至48小时联系到89%的受试者,组间疼痛水平未检测到差异。
证据类型、等级与局限
- 证据类型:随机双盲安慰剂对照试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于慢性疼痛急性加重(VAS≥70 mm)的成人患者,0.5 mg/kg或0.25 mg/kg氯胺酮20分钟输注可有效达到60分钟VAS下降20 mm的主要终点,但不良反应较安慰剂更多。
- 氯胺酮未显示在24至48小时内更长期的疼痛控制,作者结论认为氯胺酮输注对慢性疼痛急性加重有效但不良反应更多且无更长期镇痛。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Subdissociative-dose ketamine (SDDK) is used to treat acute pain. We sought to determine if SDDK is effective in relieving acute exacerbations of chronic pain.
METHODS: This study was a randomized double-blind placebo-controlled trial conducted May 2017 to June 2018 at a public teaching hospital (ClinicalTrials.gov #NCT02920528). The primary endpoint was a 20-mm decrease on a 100-mm visual analog scale (VAS) at 60 minutes. Power analysis using three groups (0.5 mg/kg ketamine, 0.25 mg/kg ketamine, or placebo infused over 20 minutes) estimated that 96 subjects were needed for 90% power. Inclusion criteria included age > 18 years, chronic pain > 3 months, and acute exacerbation (VAS ≥ 70 mm). Pain, agitation, and sedation were assessed by VAS at baseline and 20, 40, and 60 minutes after initiation of study drug. Telephone follow-up at 24 to 48 hours used a 10-point numeric rating scale for pain.
RESULTS: A total of 106 subjects were recruited, with three excluded for baseline pain < 70 mm. After randomization, 35 received 0.5 mg/kg ketamine, 36 received 0.25 mg/kg ketamine, and 35 received placebo. Three subjects receiving 0.5 mg/kg withdrew during the infusion due to adverse effects, and one subject in each group had incomplete data, leaving 97 for analysis. Initial pain scores (91.9 ± 8.9 mm), age (46.5 ± 12.6 years), sex distribution, and types of pain reported were similar. Primary endpoint analysis found that 25 of 30 (83%) improved with 0.5 mg/kg ketamine, 28 of 35 (80%) with 0.25 mg/kg ketamine, and 13 of 32 (41%) with placebo (p = 0.001). More adverse effects occurred in the ketamine groups with one subject in the 0.25 mg/kg group requiring a restraint code for agitation. A total of 89% of subjects were contacted at 24 to 48 hours, and no difference in pain level was detected between groups.
CONCLUSION: Ketamine infusions at both 0.5 and 0.25 mg/kg over 20 minutes were effective in treating acute exacerbations of chronic pain but resulted in more adverse effects compared to placebo. Ketamine did not demonstrate longer-term pain control over the next 24 to 48 hours.
参考来源
- Lumanauw DD, Youn S, Horeczko T, et al. Subdissociative-dose Ketamine Is Effective for Treating Acute Exacerbations of Chronic Pain. Acad Emerg Med. 2019. PMID: 30901130. doi:10.1111/acem.13755
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。